Sign In
15 Apr 2021 14:45
15 April 2021 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Directorate Change
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Nigel Clifford, a Non-Executive Director, will leave the Group on 30 April 2021 after serving for six years.
Nigel was appointed to Alliance's Board as a Non-Executive Director on 26 January 2015, since which time he has made a significant contribution to both the development and governance of the Group. Nigel's formal notice period has been waived by the Board owing to his other business commitments.
The recruitment process to appoint a replacement Non-Executive Director is underway and a further announcement will be made in due course.
David Cook, Alliance Pharma's Chairman, said: "On behalf of the Board, I extend our sincere thanks to Nigel for his wise counsel to the Board and its Committees as a Non-Executive Director during the past six years. During that time, Nigel has added significant value to Alliance, particularly in connection with the Group's international expansion, and we wish him well in his future endeavours."
For further information:
Alliance Pharma plc | + 44 (0)1249 466966 |
Peter Butterfield, Chief Executive Officer | |
Andrew Franklin, Chief Financial Officer | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0)20 7466 5000 |
Mark Court / Sophie Wills / Hannah Ratcliff | |
Numis Securities Limited | + 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Oliver Steele | |
Corporate Broking: James Black |
Investec Bank plc | + 44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams | |
Corporate Broking: Patrick Robb |
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
Follow the stocks
